Ocular Therapeutix (OCUL) Times Interest Earned (2013 - 2026)
Ocular Therapeutix's quarterly Times Interest Earned came in at -$33.61 in Q1 2026, down 56.92% year-on-year from -$78.02 in Q1 2025, and down 36.45% quarter-over-quarter from -$24.63 in Q4 2025.
Ocular Therapeutix has reported Times Interest Earned for 14 years, with the latest figure at -$33.61 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned fell 56.92% year-over-year to -$33.61; the trailing twelve-month figure through Mar 2026 stood at -$25.75 (down 57.87% YoY), and the FY2025 full-year result was -$22.82, down 80.32% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$33.61, down from -$24.63 in the prior quarter.
- The five-year high for Times Interest Earned was -$4.83 in Q4 2023, with the low at -$33.61 in Q1 2026.
- Average Times Interest Earned over 5 years is -$15.02, with a median of -$12.75 recorded in 2023.
- Year-over-year, Times Interest Earned jumped 53.92% in 2023 and tumbled 237.12% in 2024.
- Tracing OCUL's Times Interest Earned over 5 years: stood at -$10.48 in 2022, then jumped by 53.92% to -$4.83 in 2023, then tumbled by 237.12% to -$16.28 in 2024, then slumped by 51.28% to -$24.63 in 2025, then slumped by 36.45% to -$33.61 in 2026.
- The last three Times Interest Earned figures came in at -$33.61 (Q1 2026), -$24.63 (Q4 2025), and -$22.88 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -33.61 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.61 |
| Dec 31, 2025 | -24.63 |
| Sep 30, 2025 | -22.88 |
| Jun 30, 2025 | -22.43 |
| Mar 31, 2025 | -21.42 |
| Dec 31, 2024 | -16.28 |
| Sep 30, 2024 | -14.27 |
| Jun 30, 2024 | -13.64 |
| Mar 31, 2024 | -7.80 |
| Dec 31, 2023 | -4.83 |
| Sep 30, 2023 | -5.61 |
| Jun 30, 2023 | -10.33 |
| Mar 31, 2023 | -12.75 |
| Dec 31, 2022 | -10.48 |
| Sep 30, 2022 | -11.99 |
| Jun 30, 2022 | -11.74 |
| Mar 31, 2022 | -10.60 |
| Dec 31, 2021 | -10.74 |
| Sep 30, 2021 | -11.78 |
| Jun 30, 2021 | -12.22 |
| Mar 31, 2021 | -12.05 |
| Dec 31, 2020 | -8.31 |
| Sep 30, 2020 | -8.17 |
| Jun 30, 2020 | -10.56 |
| Mar 31, 2020 | -10.17 |
| Dec 31, 2019 | -11.86 |
| Sep 30, 2019 | -14.02 |
| Jun 30, 2019 | -13.28 |
| Mar 31, 2019 | -19.31 |
| Dec 31, 2018 | -46.21 |
| Sep 30, 2018 | -34.94 |
| Jun 30, 2018 | -29.81 |
| Mar 31, 2018 | -27.69 |
| Dec 31, 2017 | -25.95 |
| Sep 30, 2017 | -30.95 |
| Jun 30, 2017 | -39.19 |
| Mar 31, 2017 | -35.38 |
| Dec 31, 2016 | -29.84 |
| Sep 30, 2016 | -21.69 |
| Jun 30, 2016 | -26.57 |
| Mar 31, 2016 | -25.14 |
| Dec 31, 2015 | -25.18 |
| Sep 30, 2015 | -27.52 |
| Jun 30, 2015 | -23.79 |
| Mar 31, 2015 | -14.09 |
| Dec 31, 2014 | -18.54 |
| Sep 30, 2014 | -16.45 |
| Jun 30, 2014 | -23.14 |
| Mar 31, 2014 | -158.72 |
| Dec 31, 2013 | -37.57 |
| Sep 30, 2013 | -36.54 |
| Jun 30, 2013 | -27.93 |